136 related articles for article (PubMed ID: 27400882)
1. Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.
Rovera C; Mauri MC; Bertin E; Di Pace C; Paletta S; Reggiori A; De Gaspari IF; Cattaneo D; Mari D; Altamura AC
Hum Psychopharmacol; 2016 Sep; 31(5):349-55. PubMed ID: 27400882
[TBL] [Abstract][Full Text] [Related]
2. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.
Volonteri LS; Colasanti A; Cerveri G; Fiorentini A; De Gaspari IF; Mauri MC; Valli A; Papa P; Mencacci C
J Psychopharmacol; 2010 Aug; 24(8):1193-9. PubMed ID: 19406851
[TBL] [Abstract][Full Text] [Related]
4. The Effect of Food on the Single-Dose Bioavailability and Tolerability of the Highest Marketed Strength of Duloxetine.
Rizea-Savu S; Duna SN; Ghita A; Iordachescu A; Chirila M
Clin Pharmacol Drug Dev; 2020 Oct; 9(7):797-804. PubMed ID: 31793229
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
6. Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo.
Robinson M; Oakes TM; Raskin J; Liu P; Shoemaker S; Nelson JC
Am J Geriatr Psychiatry; 2014 Jan; 22(1):34-45. PubMed ID: 24314888
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
Raskin J; Wiltse CG; Siegal A; Sheikh J; Xu J; Dinkel JJ; Rotz BT; Mohs RC
Am J Psychiatry; 2007 Jun; 164(6):900-9. PubMed ID: 17541049
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
9. Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors.
Sheehan DV; Mancini M; Wang J; Berggren L; Cao H; Dueñas HJ; Yue L
Hum Psychopharmacol; 2016 Jan; 31(1):53-63. PubMed ID: 26331440
[TBL] [Abstract][Full Text] [Related]
10. Changes in energy during treatment of depression: an analysis of duloxetine in double-blind placebo-controlled trials.
Harada E; Kato M; Fujikoshi S; Wohlreich MM; Berggren L; Tokuoka H
Int J Clin Pract; 2015 Oct; 69(10):1139-48. PubMed ID: 25980552
[TBL] [Abstract][Full Text] [Related]
11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
Hellerstein DJ; Stewart JW; McGrath PJ; Deliyannides DA; Batchelder ST; Black SR; Withers A; O'Shea D; Chen Y
J Clin Psychiatry; 2012 Jul; 73(7):984-91. PubMed ID: 22901348
[TBL] [Abstract][Full Text] [Related]
13. An open-label study of duloxetine hydrochloride, a mixed serotonin and noradrenaline reuptake inhibitor, in patients with DSM-III-R major depressive disorder. Lilly Duloxetine Depression Study Group.
Berk M; du Plessis AD; Birkett M; Richardt D
Int Clin Psychopharmacol; 1997 May; 12(3):137-40. PubMed ID: 9248869
[TBL] [Abstract][Full Text] [Related]
14. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine and escitalopram for hot flushes: efficacy and compliance in breast cancer survivors.
Biglia N; Bounous VE; Susini T; Pecchio S; Sgro LG; Tuninetti V; Torta R
Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 26936232
[TBL] [Abstract][Full Text] [Related]
16. Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine.
Sheehan DV; Chokka PR; Granger RE; Walton RJ; Raskin J; Sagman D
Hum Psychopharmacol; 2011 Apr; 26(3):242-51. PubMed ID: 21681815
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine plasma level and antidepressant response.
De Donatis D; Florio V; Porcelli S; Saria A; Mercolini L; Serretti A; Conca A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jun; 92():127-132. PubMed ID: 30611837
[TBL] [Abstract][Full Text] [Related]
19. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
20. Open-label evaluation of venlafaxine sustained release in outpatients with generalized anxiety disorder with comorbid major depression or dysthymia: effectiveness, tolerability and predictors of response.
Perugi G; Frare F; Toni C; Ruffolo G; Torti C
Neuropsychobiology; 2002; 46(3):145-9. PubMed ID: 12422062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]